Michael Rice - Oct 5, 2021 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
CEO, Director
Signature
/s/ Michael Rice
Stock symbol
BLFS
Transactions as of
Oct 5, 2021
Transactions value $
-$892,812
Form type
4
Date filed
10/7/2021, 09:26 PM
Previous filing
Sep 30, 2021
Next filing
Oct 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $18.8K +11.5K +4.33% $1.64* 276K Oct 5, 2021 Direct
transaction BLFS Common Stock Sale -$466K -11.5K -4.15% $40.63 265K Oct 5, 2021 Direct F1, F2
transaction BLFS Common Stock Options Exercise $18.8K +11.5K +4.33% $1.64* 276K Oct 7, 2021 Direct
transaction BLFS Common Stock Sale -$465K -11.5K -4.15% $40.55 265K Oct 7, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -11.5K -16.67% $0.00 57.3K Oct 5, 2021 Common Stock 11.5K $1.64 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -11.5K -20% $0.00 45.8K Oct 7, 2021 Common Stock 11.5K $1.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $41.08, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.92, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019.